2020 to today · Health, Food & Regulators
Pfizer's Record: The $2.3 Billion Fraud Guilty Plea, the Nigerian Drug Trial, and the 2020 COVID Vaccine Contract
Period covered: 1992 to 2026 · 35 sources
Summary
In 2009 a Pfizer subsidiary pleaded guilty to a felony and the company paid $2.3 billion, the largest health care fraud settlement in the Justice Department's history, for selling drugs for uses the FDA had refused to approve, while, in the prosecutor's words, it was in his office settling the same conduct by a company it had just bought. In 1996 it tested an antibiotic on 200 Nigerian children during a meningitis epidemic without consent, eleven of them died, and a State Department cable later recorded that it hired investigators to dig up dirt on the Nigerian attorney general to make the case go away. In 2012 it settled bribery charges in eight countries. In 2020 the United States agreed to pay it $1.95 billion for 100 million doses of a vaccine that carried immunity from suit under a federal declaration, and when a court was asked for the trial data, the FDA proposed a schedule that would have taken more than half a century. Comirnaty brought in $36.8 billion in 2021 and $37.8 billion in 2022, and the chief executive sold $5.6 million of stock the day the results were announced.
Shiley, a company Pfizer bought, sold a heart valve that was implanted in about 86,000 people. By 1992 about 450 of the valves had fractured and nearly 300 people had died. Pfizer settled the class action in August 1992 for what it told the press would cost it between $165 million and $215 million; the settlement funds, as the court later described them, ran from a guaranteed $37.5 million patient fund to as much as $130 million for medical consultation, with $500,000 to $2 million for each fracture in the United States.
The children in Kano
In 1996, during a meningitis epidemic in northern Nigeria, Pfizer took two hundred sick children who came for treatment at a hospital in Kano, gave half of them its experimental antibiotic Trovan and half a lowered dose of an approved one, and, the children's families later alleged in federal court, did not get the consent of the children or their guardians. Eleven of the children died, five who got Trovan and six who got the comparison drug. The Second Circuit, in January 2009, held that the families had pleaded facts sufficient to state a cause of action under the Alien Tort Statute for a violation of the norm of customary international law prohibiting medical experimentation on human subjects without their consent, and sent the case back for trial; the Supreme Court declined to hear Pfizer's appeal on June 29, 2010. In July 2009 Pfizer settled with the state of Kano, specifically denying any wrongdoing, with a fund of up to $35 million for the children, $30 million for health projects, and $10 million for the state's legal costs.
A State Department cable from the embassy in Abuja dated April 20, 2009 and published by WikiLeaks in December 2010 records what Pfizer's country manager told American diplomats about how the federal case was handled: that Pfizer had hired investigators to uncover corruption links to Federal Attorney General Michael Aondoakaa to expose him and put pressure on him to drop the federal cases, that Pfizer's investigators were passing this information to local media, and that the attorney general's cronies were pressuring him to drop the suit for fear of further negative articles. Pfizer told the Guardian that the statements purportedly contained in such documents are completely false.
The plea
On September 2, 2009 the Justice Department announced the largest health care fraud settlement in its history. Pfizer's subsidiary Pharmacia and Upjohn pleaded guilty to a felony under the Food, Drug and Cosmetic Act for misbranding Bextra with the intent to defraud or mislead; Pfizer had promoted the painkiller for uses and doses the FDA specifically declined to approve due to safety concerns. The criminal fine was $1.195 billion, the largest criminal fine ever imposed in the United States for any matter, plus $105 million forfeited. The company paid another $1 billion to settle civil claims that it had illegally promoted Bextra, the antipsychotic Geodon, the antibiotic Zyvox, and the epilepsy drug Lyrica. Six whistleblowers shared more than $102 million.
It was not the first time. In May 2004 Warner-Lambert, which Pfizer had bought in 2000, pleaded guilty and paid $430 million over the promotion of Neurontin for unapproved uses. In April 2007 Pharmacia subsidiaries paid $34.7 million over the growth hormone Genotropin. The acting United States attorney in Boston, Mike Loucks, said in 2009: at the very same time Pfizer was in our office negotiating and resolving the allegations of criminal conduct by its then newly acquired subsidiary, Warner-Lambert, Pfizer was itself in its other operations violating those very same laws.
The bribes
On August 7, 2012 the Securities and Exchange Commission charged Pfizer with violating the Foreign Corrupt Practices Act; its subsidiaries in Bulgaria, China, Croatia, the Czech Republic, Italy, Kazakhstan, Russia, and Serbia had made improper payments to foreign officials to obtain regulatory and formulary approvals, sales, and increased prescriptions. The head of the SEC's unit said the bribery was so entwined in their sales culture that they offered points and bonus programs to improperly reward foreign officials who proved to be their best customers. A Pfizer subsidiary admitted paying more than $2 million in bribes between 1997 and 2006 and making more than $7 million in profit from them, and paid a $15 million penalty under a deferred prosecution agreement; with the SEC settlements the total was about $60 million.
The contract
On July 22, 2020 the Department of Health and Human Services and the Department of Defense announced that the government would pay Pfizer $1.95 billion for the first 100 million doses of its COVID-19 vaccine once it was authorized, with an option on 500 million more, and on December 23 it bought 100 million more for the same price. Pfizer took no federal money for development, and its chief executive, Albert Bourla, explained why on September 13, 2020: When you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. I didn't want to have any of that. And also, I wanted to keep Pfizer out of politics, by the way. Its partner BioNTech took up to 375 million euros from the German government that same month, and had taken $55 million from the Gates Foundation the year before.
The government had already made sure the company could not be sued. On March 10, 2020 the Secretary of Health and Human Services signed a declaration under the Public Readiness and Emergency Preparedness Act, effective February 4, that gave manufacturers, distributors, and program planners immunity from any claim of loss caused by, arising out of, relating to, or resulting from the manufacture, distribution, administration, or use of medical countermeasures, except for willful misconduct. The Secretary's own reading was that the Act precludes, for example, liability claims alleging negligence by a manufacturer in creating a vaccine. What is left is a federal compensation program. Its own figures as of August 1, 2026: 14,169 claims filed over COVID-19 countermeasures, 11,104 of them over the vaccines; 7,790 decided; 112 found eligible; 62 paid; 7,678 denied, 3,209 of them for not submitting medical records and 2,674 for missing the filing deadline.
The results and the stock
On November 18, 2020 Pfizer announced that its trial had met its endpoints with a vaccine efficacy rate of 95 percent, based on 170 cases of COVID-19, 162 in the placebo group and 8 in the vaccine group. On December 11 the FDA issued the first emergency use authorization for a COVID-19 vaccine, for people 16 and older, citing the same 170 cases and safety data on 37,586 participants with a median of two months of follow-up after the second dose. On August 23, 2021 the FDA licensed it as Comirnaty, and the same announcement said the data demonstrate increased risks of myocarditis and pericarditis, particularly within the seven days following the second dose, with the observed risk highest in males 12 through 17 years of age.
On November 9, 2020, the day Pfizer first announced that the vaccine worked, Bourla sold 132,508 shares at $41.94, $5.56 million, under a trading plan he had adopted on August 19, 2020, according to the Form 4 he filed with the SEC the next day. Comirnaty brought the company $36.8 billion in 2021 and $37.8 billion in 2022, and Paxlovid another $18.9 billion in 2022, in a year when Pfizer's total revenue was $100.3 billion, an all-time high for Pfizer in its own words.
The data
In 2021 a group of doctors and scientists asked the FDA under the Freedom of Information Act for the documents it had relied on to license the vaccine. The FDA told the court there were more than 329,000 pages and proposed to release 500 pages a month, a schedule the plaintiffs calculated at 54 years and 10 months, and at about 75 years once the FDA found more records. On January 6, 2022 Judge Mark Pittman in Fort Worth wrote that there may not be a more important issue at the Food and Drug Administration than the pandemic, the Pfizer vaccine, getting every American vaccinated, and making sure that the American public is assured that this was not rushed on behalf of the United States, found the request to be of paramount public importance, and ordered 55,000 pages a month.
The label
On June 25, 2021 the FDA added a warning to the Pfizer and Moderna fact sheets that reports of adverse events suggest increased risks of myocarditis and pericarditis, particularly following the second dose. The CDC's data at the time put the reporting rate after a second dose at 62.8 cases per million for males 12 to 17 and 50.5 per million for males 18 to 24, with 96 percent of the confirmed cases hospitalized, and its advisory committee concluded the benefits clearly outweigh the risks in all populations. On June 25, 2025 the FDA approved a required update to the Comirnaty and Spikevax labels putting the incidence at about 8 cases per million doses overall and about 27 per million in males 12 to 24 for the 2023 to 2024 formula, and noting a follow-up study in which some patients still had abnormal cardiac MRI findings whose clinical and prognostic significance is not known.
The contracts abroad
Public Citizen obtained nine of Pfizer's vaccine contracts and published them in October 2021. Brazil expressly and irrevocably waives any right of immunity which either it or its assets may have, was prohibited from making any public announcement concerning the existence, subject matter or terms of the agreement, and could not accept donated Pfizer doses from other countries without Pfizer's permission; Colombia, Peru, and the Dominican Republic waived immunity against precautionary seizure of any of its assets; disputes went to private arbitration in New York. The Bureau of Investigative Journalism reported in February 2021 that in Argentina and Brazil, Pfizer asked for sovereign assets to be put up as collateral for any future legal costs, which might include federal bank reserves, embassy buildings or military bases. Argentina's health minister said Pfizer misbehaved with Argentina. Its intolerance with us was tremendous.
The states, and Congress
Texas sued Pfizer on November 30, 2023 under its consumer protection law over the 95 percent claim and over what it called efforts to silence critics. A federal judge in Lubbock dismissed the case on December 30, 2024, finding that the Defendant is entitled to immunity under the Public Readiness and Emergency Act, that federal law preempts the claims, and that the company's statements were not connected to any trade or commerce; Texas appealed, and the Fifth Circuit heard argument at the start of September 2026. Kansas sued in June 2024; Pfizer moved the case to federal court and a federal judge sent it back to state court in May 2025, where it is pending.
Pfizer's own lobbying disclosures put its federal lobbying at $10.9 million in 2020, $10.3 million in 2021, $11.4 million in 2022, $14.1 million in 2023, $8.9 million in 2024, and $12.6 million in 2025, not counting the outside firms it pays. Its political action committee gave $2.0 million to federal candidates in the 2020 cycle, $1.6 million in 2022, and $1.4 million in 2024. In January 2025 the company paid $59.7 million to settle claims that a subsidiary it had bought paid doctors to prescribe a migraine drug, without admitting liability.
Primary Sources (35)
Documents, court filings, official reports, and broadcasts cited in this report.
Documented Records (1)
Chronological entries extracted from the primary sources above.
Timeline Events (7)
Dated events from this investigation in the site timeline.
More in Health, Food & Regulators
View all stories in Health, Food & Regulators → · Topic overview →
- 2017 to 2026COVID-19 Hospital Payment Bonuses, Remdesivir Approval, PREP Act Hospital Immunity, and Pre-2020 Pandemic PlansIn 2020 Congress paid hospitals 20 percent more for every Medicare patient with a COVID-19 diagnosis and then added a bonus for new treatments, the Food and Drug Administration approved remdesivir seven days after the World Health Organization's own trial found it had little or no effect on death, the government told the public not to take ivermectin in words a federal appeals court later said it had no authority to use, and the March 2020 declaration that gave drugmakers immunity was read by a state supreme court in 2026 to shield a hospital from a patient's death. The plans written before the pandemic had said not to do most of what was done: the government's 2017 guidance said an exposed household in a severe pandemic should stay home for up to three days, and the WHO's 2019 guidance said quarantine of the exposed and contact tracing were not recommended in any circumstances. At a Senate roundtable on September 28, 2026, patients, relatives, nurses, and doctors described what they say was done to patients in hospitals; no hospital or health agency took part, and the senator's office has released no report on it.Health, Food & Regulators
- 2007 to 2026The August 2026 Tariff Waiver for 660 Million Pounds of Foreign Beef Six Days After JBS Met the PresidentOn August 26, 2026 the President signed a proclamation letting 300,000 metric tons of foreign lean beef trimmings, about 660 million pounds, into the country over three months at the low in-quota tariff instead of the 26.4 percent rate that applies above the quota, on the stated ground that ground beef had become too expensive. The Wall Street Journal reported that six days earlier the co-owner of JBS, Joesley Batista, had met the President in the Oval Office and argued for exactly that; the announcement came the next day, and the White House said the decision "was not done as the result of any one conversation." JBS is the Brazilian company whose owners pleaded guilty in the United States in 2020 to bribery, admitted in Brazil to paying nearly 1,900 politicians, and bought their American packing plants with money from a Brazilian state bank. In 2017 the Agriculture Department had halted fresh Brazilian beef after refusing 11 percent of it at the border against 1 percent for the rest of the world. Since 2015 beef in the store has not had to say what country it came from. The week the quota opened, Europe stopped taking Brazilian beef over antibiotic use, the American cattle herd stood at its smallest since 1951, cattle prices fell, and the retail price of ground beef was $6.92 a pound.Health, Food & Regulators
- 1984 to 2026Anthony Fauci's Record: Private Mask Emails, Wuhan Lab Grants, Preemptive Pardon, and Pleadings of the FifthAnthony Fauci ran the National Institute of Allergy and Infectious Diseases for 38 years, was the highest paid employee of the federal government, and in 2020 became the government's voice on the pandemic. The government's own documents record: the email in which he told a cabinet secretary that masks are not really effective and that he did not recommend one, a month before he said the same on television and four months before he explained the advice had been about preserving supply; the herd immunity number he said he nudged up as the polls moved; the six-foot rule that, in his words to Congress, sort of just appeared; the Senate testimony that NIH had not funded a kind of research in Wuhan, and the NIH letter five months later describing an experiment there that EcoHealth failed to report; the audit, the suspension, and the debarment of the grantee; the pardon covering January 2014 to January 2025; the emails in which he wrote please delete this e-mail after you read it; and the day in July 2026 when, under subpoena, he invoked the Fifth Amendment more than a hundred times, after which a Senate committee voted to hold him in contempt.Health, Food & Regulators
- 2021 to 2026The 2026 Health Insurance Premium Spike After ACA Tax Credits ExpiredThe larger premium credits that had made insurance on the exchanges affordable since 2021 expired on December 31, 2025. Congress shut the government for 43 days over them in the fall, took a Senate vote that failed, passed a three year extension in the House in January by 230 to 196, and let it die. Enrollment fell from 22.1 million to 19.2 million, premium payments rose 58 percent for the people who stayed, deductibles rose $1,000, and the budget office expects more than 4 million more people uninsured by 2034, on top of the 10 million from the July 2025 law.Health, Food & Regulators
- 2018 to 2026Boeing 737 MAX Crashes: How the FAA Let Boeing Certify Its Own Planes and the DOJ Dropped Criminal ChargesTwo new Boeing 737 MAX jets crashed in October 2018 and March 2019, killing 346 people, because of a flight control system the company had not fully disclosed to the regulator, the airlines, or the pilots. A congressional investigation found a horrific culmination of faulty assumptions, a lack of transparency, and grossly insufficient oversight by the FAA, which had delegated much of the plane's certification to Boeing's own employees. The Justice Department charged the company with fraud and let it defer prosecution for $2.5 billion. Boeing broke the agreement, a door blew off another MAX in 2024, and in 2025 the government dropped the charge for $1.1 billion. A federal judge said the deal failed to secure the necessary accountability, and that he could not stop it.Health, Food & Regulators